Dr. Stuart Schnitt from Brigham and Women Hospital in Boston discusses his team's recent findings of variable architectural and cytological patterns of residual disease in breast cancer patients with incomplete pathologic response. The relationship of pattern of residual disease to pre-treatment clinicopathologic parameters and the potential impact on management are discussed.

Associated article: Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. https://www.nature.com/articles/s41379-020-00714-5